GlaxoSmithKline

GlaxoSmithKline Consumer Healthcare splits media account between GroupM and OMG

Author

By Ishbel Macleod, PR and social media consultant

September 4, 2013 | 1 min read

GlaxoSmithKline (GSK) Consumer Healthcare has announced the appointment of GroupM and Omnicom Media Group to handle the majority of its global media planning and buying account.

Omnicom’s PHD is set to handle North America and West Africa, while GroupM will cover the rest of the world, including Latin America, Europe and Asia.

However, Dentsu will continue to retain the pharmaceutical company’s media buying in Japan, although it will work with GroupM.

GSK vice-president global media Sam Singh said: “The decision to consolidate our media investment with two network partners – GroupM and OMG, with Dentsu buying in Japan, is based on various factors including simplicity and speedier deployment of best practices. We believe this sets us up with a fit for purpose media system into the future.

“We continue to hold the outgoing agencies, Starcom and Carat, in the highest of regard. They have consistently exhibited high levels of professionalism and we wish them all the very best.”

The agencies will be tasked with media strategy, planning and buying for the account, estimated at $1.5bn.

GlaxoSmithKline

Content created with:

GroupM

GroupM is the world’s leading media investment company with a mission to create a new era of media where advertising works better for people. Responsible for more...

Find out more

Omnicom Group

A global leader in marketing communications, Omnicom provides brand and advertising services to over 5000 clients in over 100 countries.

Find out more

PHD UK

PHD is known globally as an innovator in communications planning and buying across broadcast, print, digital, mobile, social and emerging media and was named as...

Find out more

Dentsu

Dentsu Inc. is a Japanese international advertising and public relations joint stock company headquartered in Tokyo. Dentsu is currently the largest advertising...

Find out more

More from GlaxoSmithKline

View all

Trending

Industry insights

View all
Add your own content +